These results suggest that XMU-MP-1 inhibits NFκB target gene expression in a dose- and time-dependent manner and that this downregulation is not due to a change in the abundance of p65, a major subunit of NFκB in ccRCC (32). Here, NFKB1 is linked to nonpapillary renal cell carcinoma.